Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16

Clinical and Experimental Immunology

Volumn 115, Issue 3, 1999, Pages 397-403

  Fernando, Germain J P ^a,b   Murray, B ^a   Zhou, J ^a   Frazer, I H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Cervical cancer; Oncogene protein; Tumour regression; Vaccine

Indexed keywords

CANCER VACCINE; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG PURIFICATION; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; SUBCUTANEOUS DRUG ADMINISTRATION; UTERINE CERVIX CARCINOMA; VACCINE PRODUCTION; VIRUS CARCINOGENESIS; WART VIRUS;

ANIMALS; ANTIBODIES, VIRAL; BASE SEQUENCE; CANCER VACCINES; CHROMATOGRAPHY, ION EXCHANGE; DNA PRIMERS; ESCHERICHIA COLI; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT FUSION PROTEINS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0032995535     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00813.x     Document Type: Article

References (32)

1. Tindle RW, Frazer IH. Human papillomavirus infection, genital warts and cervical cancer: prospects for prophylactic and therapeutic vaccines. Exp Opin Invest Drugs 1995; 4:783-97.
2. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802.
3. Galloway DA. Human papillomavirus vaccines: a warty problem. Infect Agents Dis 1994; 3:187-93.
4. zur Hausen H, de Villiers EM. Human papilloma viruses. Annu Rev Microbiol 1994; 48:427-47.
5. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989; 8:3905-10.
6. Lin KY, Guarnieri FG, Staveley OCKF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56:21-26.
7. von Knebel Doeberitz M, Rittmuller C, Aengeneyndt F, Jansen-Durr P, Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. J Virol 1994; 68:2811-21.
8. Seedorf K, Oltersdorf T, Krammer G, Rowekamp W. Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J 1987; 6:139-44.
9. Selvey LA, Dunn LA, Murray B, Tindle RW, Frazer IH. An ELISA capture assay for the E7 transforming proteins of HPV 16 and HPV 18. J Virol Methods 1992; 37:119-27.
10. Aida Y, Pabst MJ. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 1990; 132:191-5.
11. Dalsgaard K. Saponin adjuvants. 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in foot-and-mouth disease vaccines. Arch Gesamte Virusforsch 1974; 44:243-54.
12. Fernando GJ, Stewart TJ, Tindle RW, Frazer IH. Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term. Scand J Immunol 1998; 47:459-65.
13. Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23:2242-9.
14. Herd K, Fernando GJ, Dunn LA, Frazer IH, Lambert P, Tindle RW. E7 oncoprotein of human papillomavirus type 16 expressed constitutively in the epidermis has no effect on E7-specific B-or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein. Virology 1997; 231:155-65.
15. Fernando GJ, Tindle RW, Frazer IH. T-helper epitopes of the E7 transforming protein of cervical cancer associated human papillomavirus type 18 (HPV 18). Virus Res 1995; 36:1-13.
16. Cole KD, Fernando-Warnakulasuriya GJ, Boguski MS, Freeman M, Gordon JI, Clark WA, Law JH, Wells MA. Primary structure and comparative sequence analysis of an insect apolipoprotein. Apolipophorin-III from Manduca sexta. J Biol Chem 1987; 262:11794-800.
17. Fernando GJ, Stenzel DJ, Tindle RW, Merza MS, Morein B, Frazer IH. Peptide polymerisation facilitates, incorporation into ISCOMs and increases antigen-specific IgG2a production. Vaccine 1995; 13:1460-7.
18. Park DS, Selvey LA, Kelsall SR, Frazer IH. Human papillomavirus type 16, E6, E7 and L1 and type 18 E7 proteins produced by recombinant baculoviruses. J Virol Methods 1993; 45:303-18.
19. Tindle RW, Zhou WD, Saul A, Frazer IH. The molecular specificity of linear B-epitopes in the E7 open reading frame protein of human papillomavirus 16 defined by monoclonal antibodies. Pept Res 1990; 3:162-6.
20. Armstrong DJ, Roman A. The anomalous electrephoretic behavior of the human papillomavirus type 16 E7 protein is due to the high content of acidic amino acid residues. Biochem Biophys Res Commun 1993; 192:1380-7.
21. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243:934-7.
22. Lee JO, Russo AA, Pavletich NP. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 1998; 391:859-65.
23. Patrick DR, Zhang K, Defeo-Jones D, Vuocolo GR, Maigetter RZ, Sardana MK, Oliff A, Heimbrook DC. Characterization of functional HPV-16 E7 protein produced in Escherichia coli. J Biol Chem 1992; 267:6910-5.
24. Sato H, Watanabe S, Furuno A, Yoshiike K. Human papillomavirus type 16 E7 protein expressed in Escherichia coil and monkey COS-1 cells: immunofluorescence detection of the nuclear E7 protein. Virology 1989; 170:311-5.
25. Chinami M, Yuge K, Kawano K, Shingu M. Refolding and purification of human papillomavirus type 16 E7-lacZ fusion protein expressed in Escherichia coli. Protein Expr Purif 1991; 2:175-8.
26. Kasher MS, Wakulchik M, Cook JA, Smith MC. One-step purification of recombinant human papillomavirus type 16 E7 oncoprotein and its binding to the retinoblastoma gene product. Biotechniques 1993; 14:630-47.
27. Caner JJ, Yaegashi N, Jenison SA, Galloway DA. Expression of human papillomavirus proteins in yeast Soccharomyces cerevisiae. Virology 1991; 182:513-21.
28. Imai Y, Matsushima Y, Sugimura T, Terada M. Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product. J Virol 1991; 65:4966-72.
29. Pahel G, Aulabaugh A, Short SA, Barnes JA, Painter GR, Ray P, Phelps WC. Structural and functional characterization of the HPV 16 E7 protein expressed in bacteria. J Biol Chem 1993; 268:26018-2.
30. Roth EJ, Kurz B, Liang L, Hansen CL, Dameron CT, Winge DR, Smotkin D. Metal thiolate coordination in the E7 proteins of human papilloma virus 16 and cottontail rabbit papilloma virus as expressed in Escherichia coil. J Biol Chem 1992; 267:16390-5.
31. Braspenning L, Manetti R, Zumbach K, Meschede W, Gissmann L, Tommasino M. A general purification protocol for E7 proteins from "high- and low-risk" human papillomavirus types expressed in the east Schizosaccharomyces pombe. Protein Expr Purif 1997; 10:192-201.
32. Sundaram P, Brandsma JL. Rapid, efficient, large-scale purification of unfused, non-denatured E7 protein of cottontail rabbit papillomavirus. J Virol Methods 1996; 57:61-70.